The pathogenicity of a double mutant of pseudorabies virus (PRV) with deletions in the latency gene and the early protein O gene was examined. In comparison to the parent Indiana-Funkhauser virus, the ability of this mutant to replicate and to cause disease in piglets is greatly reduced. At an infection dose that caused no clinical signs in 5-day-old neonatal piglets, this mutant was capable of eliciting solid protective immunity against a lethal PRV challenge. Thus, the double-gene deletion attenuates PRV but does not affect its immunogenicity. These features may be desirable for inclusion into future PRV vaccines.
Pseudorabies (Aujeszky's disease) is a contagious disease of swine caused by a herpesvirus belonging to the a-herpesvirus subfamily. 7 Younger pigs, in general, are more susceptible and exhibit more severe clinical signs, including central nervous system (CNS) signs, than do older animals. In pigs that recover from the acute infection, pseudorabies virus (PRV) persists in a latent state from which the virus can be reactivated and transmitted to susceptible animals. Thus, latent virus is a reservoir of the disease and an obstacle for disease eradication.
The PRV genome is a linear duplex DNA molecule with a molecular mass of approximately 90 x 10 6 Daltons and an estimated coding capacity for up to 100 viral genes. 1 More than 80 PRV-specific RNAs have been detected and mapped to various regions of the viral genome. The expression of PRV genes is coordinately regulated with 3 classes of mRNA synthesized during a productive infection: 1) immediate-early mRNA is synthesized before protein synthesis; 2) early mRNA is synthesized before viral DNA replication; and 3) late mRNA is synthesized after viral protein translation and DNA replication.
During PRV latency, there is limited viral gene expression, 4,8-10 and a 8.5-kb long latency transcript (LLT) has been described. 5 The direction of transcription of LLT is antiparallel to that of 2 other PRV genes: the essential immediate-early gene IE180 and the nonessential early protein O (EPO) gene. The LLT gene overlaps the entire IE180 gene and most of the EPO gene.
Recently, a PRV mutant (ELß) with deletions in the LLT and EPO genes was constructed. 6 The essential features of ELß are depicted in Fig. 1 . A portion (an 828-bp StuI-NcoI fragment) of the BamHI-P fragment was excised and replaced by the Escherichia coli lac-Z (ß-galactosidase) gene under the control of the PRV gX gene promoter. Because of the dual coding nature of the StuI-NcoI fragment, deletions were made in the latency gene and in the EPO gene. In the rightward direction, most of the N-terminal coding sequence and the donor splice site of LLT were removed. In the leftward orientation, a substantial part of EPO is deleted, which includes the translation initiation codon through the cysteine-rich zinc finger domain. The zincfinger domain of EPO was deliberately removed because this motif also is present in the homologous ICPO gene of herpes simplex virus type 1 (HSV-1). The HSV-1 ICPO gene is associated with the transactivation of HSV-1 genes 2,3 and the reactivation of HSV from an in vitro latency model. 12 Prior studies showed that the replication of ELß in tissue culture was greatly reduced and that weaned pigs infected with ELß were also asymptomatic. 6 Because young pigs are more susceptible to PRV infection, studies investigating the virus shedding pattern, clinical manifestations, and the potential protective immunity of this mutant PRV in neonatal piglets were conducted.
Materials and methods
Viruses and cells. The prototype PRV used was the virulent Indiana-Funkhauser (InFh) strain. The mutant virus, EL& was derived from the InFh virus ( Fig. 1 ). Both viruses were propagated and titered on Madin-Darby bovine kidney (MDBK) cells. The MDBK cells were grown in Eagle's minimal essential medium (EMEM) containing 10% heat-inac- tivated fetal bovine serum (FBS) supplemented with 0.22% sodium bicarbonate, 0.25% lactalbumin hydrolysate, 0.01% sodium pyruvate, and 50 µg/ml gentamicin sulfate.
Nasal and pharyngeal swab samples. The nasal passages and the dorsal pharyngeal/tonsillar region were swabbed separately in piglets given the highest doses of ELP and InFh viruses. Each swab was submerged immediately into 2 ml of cold EMEM containing 2% FBS, penicillin (25 U/ml), streptomycin (25 µg/ml), neomycin sulfate (25 µg/ml), bacitracin (0.25 U/ml), and gentamicin sulfate (50 µg/ml) and stored at -70 C. For analysis, swabs were thawed and squeezed with sterile forceps, and the supernatant was spun at low speed to remove debris. Sample supernatants (100 µl) were inoculated onto confluent MDBK cells grown in 60-x 15mm tissue culture dishes. After 1 hr incubation at 37 C, 5 ml of a 0.6% agarose overlay in EMEM containing 2% FBS and 50 µg/ml gentamicin sulfate was added, and the cultures were incubated for an additional 2-3 days at 37 C in a humidified CO 2 incubator. Plaques were counted after cultures were fixed in 100% methanol and stained with 0.1% crystal violet. 11
Virus neutralization test. Sera were heat inactivated at 56 C for 30 min. Twofold dilutions were prepared, and the virus neutralizing (VN) antibody titer was determined. The VN titer is reported as the reciprocal of the serum dilution causing a PRV plaque reduction of 50% on MDBK cells.
Challenge exposure. Piglets used in these studies were first determined to be negative for PRV antibody. Each piglet was housed individually in a virus-tight plexiglass isolator. Fiveday-old piglets were inoculated with different doses of the ELß or InFh virus intranasally. All ELß-infected piglets were housed in 1 room under negative pressure, and the InFhinfected piglets were housed in a second isolation room. At designated times, ELß-infected piglets and age-matched control piglets were transferred to clean plexiglass chambers and challenged with 1 x 10 7 plaque-forming units (PFU)/nostril of virulent InFh virus. Both vaccinated and unvaccinated piglets were monitored for clinical signs following challenge exposure.
Animal experiment. Thirty-eight 5-day-old piglets were distributed randomly into 4 groups, and each group was inoculated with an increasing dose of PRV. Group I, group II, group III, and group IV animals received virus at 5 x 10 3 , 5 x 10 4 , 5 x 10 5 , and 1.4 x 10 6 PFU/nostril, respectively. Half of the piglets in each group received ELß and half of the piglets that were in a separate isolation room received InFh virus as a virulent virus control.
Results
Virus shedding. Virus replication studies were carried out only with group IV animals inoculated with the highest virus dose (1.4 x 10 6 PFU/nostril). The pharyngeal and nasal areas were swabbed daily for 8 days following virus inoculation of both ELß-infected (B group) and InFh-infected (T group) piglets (Tables 1, 2). The results indicated that ELß replicated less extensively than the parent virus in these neonatal animals. With the pharyngeal samples, 6 of 7 T-group piglets were shedding > 100 PFU/0.1 ml on the first day postinoculation (PI) and all 7 piglets were shedding extensive amounts of InFh virus by the second day PI. The InFh-infected piglets continued to shed large amounts of virus until they died on days 4 and 5 PI. In contrast, only 2 of 7 B-group piglets (B6 and B8) shed > 100 PFU/0.1 ml of ELß virus during the 8-day interval following exposure. By day 8 PI, ELß was recovered from the pharyngeal region only from piglets B6 and B8. Virus was more difficult to recover from the nasal cavity of inoculated piglets. InFh virus was recovered from the nasal cavity of all T-group piglets; however, B-group piglets shed only low levels of ELß from the nasal region (Table 2 ). Nevertheless, it was possible to recover ELß from all of the B-group piglets either by nasal or pharyngeal swabbing.
Clinical signs and mortality. At the higher inoculating dose of ELß clinical signs in the infected animals became more apparent. Piglets infected with the lowest dose, 5 x 10 3 PFU/nostril, of ELß showed no clinical signs of PRV infection. At 5 x 10 4 PFU/nostril, 2 piglets were normal and 2 piglets were off feed and depressed. At 5 x 10 5 and 1.4 x 10 6 PFU/nostril, all 11 infected animals were inappetent and depressed and had some diarrhea (Table 3) . At equivalent infectious matched naive piglets that were challenged with 1 x 10 7 PFU/nostril of InFh virus on day 12 after inoculation with ELß The second experiment involved the ELß-infected piglets in groups I and II. Four animals doses, all InFh-infected animals showed more severe clinical signs than did the ELß-infected animals.
At the 3 lower virus doses, all the ELß-infected piglets survived, whereas 4 of 4 and 3 of 4 animals infected with 5 x 10 5 and 5 x 10 4 PFU/nostril of InFh virus, respectively, died (Table 4 ). Among the group IV animals given the highest virus dose (1.4 x 10 6 PFU/ nostril), 4 of 7 B-group piglets died and 7 of 7 T-group piglets died. The time of death for the B-group piglets Table 3 . Responses and protection of 5-day-old piglets vaccinated nasally with ELß and challenged with 1 x 10 7 PFU/nostril InFh. from each group and 4 age-matched naive piglets were challenged. All 12 animals were exposed to 1 x 10 7 PFU/nostril of InFh virus on day 17 after inoculation with ELß The results showed that all 10 naive control animals became anorexic and depressed, 3 showed CNS signs, and all 10 animals died within 5-8 days postchallenge. In contrast, all 11 piglets with prior exposure to ELß showed no noticeable clinical signs (Table 3) . Even the group I piglets exposed to 5 x 10 3 PFU/ nostril of ELß virus were solidly protected.
Discussion
In this study, we analyzed a recombinant PRV with deletions in the latency and EPO genes in terms of its ability to replicate, to cause disease, and to induce protective immunity in 5-day-old piglets. Replication of the PRV mutant, ELß, in the upper respiratory tract of pigs is dramatically reduced when compared with that of the parent InFh virus. However, ELß does replicate in young piglets and must be kept below a threshold level to prevent severe clinical signs. At doses above 10 6 PFU/nostril of ELß, mortality occurred in the neonatal piglets. An equivalent dose of ELß inoculated into weaned pigs caused only a fever of short duration in 1 of 5 animals. 6 As expected, PRV, including ELß is more pathogenic for younger piglets than for older piglets.
The reduced virulence of ELß as compared with the parent PRV is also clearly shown at the lower virus dosages. Doses of 5 x 10 4 and 5 x 10 5 PFU/nostril that were fatal for InFh-infected piglets were not fatal for the ELß-infected piglets. At a dose of 5 x 10 3 PFU/ nostril of ELß, the infection was subclinical in 4 of 4 piglets. Even at this subclinical dose, which induced only a weak humoral immune response to PRV, all ELß-exposed piglets were fully protected from a lethal challenge dose of PRV. Our data demonstrate that ELß is attenuated and could elicit complete protective immunity in very young piglets in as little as 12 days following vaccination.
The results from this study together with those ob-tained previously, suggest that ELß exhibits several features that are desirable in a PRV vaccine. Current genetically engineered PRV vaccines all contain a thymidine kinase gene deletion coupled with the removal of one or more nonessential glycoproteins for diagnostic purposes. Mutations in the EPO and the LLT genes incorporated into current vaccines will further reduce their virulence while preserving the full complement of immunogenic proteins.
